Get in touch
Navigation
  • Home
  • Team
  • Companies
  • News & Ideas
  • Careers
  • Investor Portal
  • Contact Us
Address
Bold Capital Partners
225 Santa Monica Blvd.
Suite 900
Santa Monica
CA 90401
Google Maps
Contacts
Email us
Socials
LinkedIn
Recent Investments
Figure AI
Figure AI
Omeat
Omeat Omeat
Immunis Biomedical
Immunis Biomedical Immunis Biomedical

Insilico Medicine

 - 
Insilico Medicine -  Insilico Medicine - 
Insilico Medicine Insilico Medicine
Insilico is utilizing and developing the latest innovations in artificial intelligence to bridge the gap between biomarker development and drug discovery. Insilico’s comprehensive drug discovery engine drastically reduces the time and cost of identifying promising drug candidates.
Visit Company Website
Alex Zhavoronkov
Alex Zhavoronkov CEO
Technologies
  • Applied AI,
  • Biotechnology,
  • Computational Biology
  • Follow
  • LinkedIn
  • Twitter
  • Company News
    View All News
                     Insilico Medicine Is Developing New Inhalable Formulation of First Generative AI Drug
    07.19.23
    Healthcare
    Insilico Medicine Is Developing New Inhalable Formulation of First Generative AI Drug
                     Hong Kong-Based Biotech Insilico Medicine Shifts IPO Plan to City from New York
    06.28.23
    Healthcare
    Hong Kong-Based Biotech Insilico Medicine Shifts IPO Plan to City from New York
                     First AI-Generated Drug Enters Human Clinical Trials, Targeting Chronic Lung Disease Patients
    06.28.23
    Healthcare
    First AI-Generated Drug Enters Human Clinical Trials, Targeting Chronic Lung Disease Patients
                     Insilico Medicine Receives IND Approval for Novel AI-Designed USP1 Inhibitor for Cancer
    05.25.23
    Healthcare
    Insilico Medicine Receives IND Approval for Novel AI-Designed USP1 Inhibitor for Cancer
                     Insilico Medicine Successfully Discovered Potent, Selective, and Orally Bioavailable Small Molecule Inhibitor of CDK8 to Treat Cancer Using Generative AI
    04.24.23
    Healthcare
    Insilico Medicine Successfully Discovered Potent, Selective, and Orally Bioavailable Small Molecule Inhibitor of CDK8 to Treat Cancer Using Generative AI
                     Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19
    02.23.23
    Healthcare
    Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19

    Jobs

    Interested in a job at Insilico Medicine?
    View Jobs
    Proprio
    Proprio
    Next